安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Riluzole - Wikipedia
Riluzole is a medication used to treat amyotrophic lateral sclerosis (ALS) and other motor neuron diseases Riluzole delays the onset of ventilator -dependence or tracheostomy in some people and may increase survival by two to three months [5] Riluzole is available in tablet and liquid form
- Riluzole Uses, Side Effects Warnings - Drugs. com
Riluzole is used to treat amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease Riluzole is not a cure for ALS, but it may delay progression of the disease and prolong your life
- Riluzole (oral route) - Side effects dosage
Riluzole is used to treat patients with amyotrophic lateral sclerosis (ALS), which is also known as Lou Gehrig's disease Riluzole is not a cure for ALS, but it may extend survival for patients in the early stages of the disease or extend the time until a tracheostomy (breathing tube in the throat) is needed
- Riluzole (Exservan, Rilutek, Tiglutik): Uses, Side Effects . . . - WebMD
Overview: Riluzole is used to treat amyotrophic lateral sclerosis (ALS), which is also known as Lou Gehrig’s disease Common side effects include feeling unusually weak or tired, nausea, stomach
- Riluzole: Uses, Interactions, Mechanism of Action | DrugBank Online
Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS) Riluzole extends survival and or time to tracheostomy
- Riluzole Tablets - Cleveland Clinic
Riluzole Tablets What is this medication? RILUZOLE (RIL yoo zole) treats amyotrophic lateral sclerosis (ALS) It works by protecting nerve cells, which delays worsening symptoms
- Riluzole (Rilutek): Uses, Side Effects, Dosage Reviews - GoodRx
Learn about riluzole (Rilutek) usage and dosing Read the latest news and reviews about the drug as well as potential side effects and popular alternatives
- Stage at which riluzole treatment prolongs survival in patients with . . .
Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial A key question is whether the survival benefit occurs at an early
|
|
|